GlobeNewswire by notified

Tecan schedules conference call on March 14 to discuss Full-Year 2022 Financial Results

Share

Männedorf, Switzerland, March 7, 2023 – The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media conference call to discuss the full-year 2022 financial results on Tuesday, March 14, 2023 at 09:00 am CET. The press release with the 2022 full-year financial results and the Annual Report 2022 will be published on March 14, 2023 at 6:30 am CET.

The conference call will be audio-webcast with synchronized presentation slides. A link to the webcast will be made available in the "Investor Relations" section of Tecan's website www.tecan.com immediately prior to the event.

Interested parties can also listen to the conference by phone.
The dial-in numbers for the call are as follows:
Participants from Europe: +41 58 310 50 00 or +44 207 107 0613 (UK)
Participants from the U.S.: +1 631 570 5613

Participants should if possible dial in 15 minutes before the start of the event.

A replay of the webcast will be available after the presentation on the website www.tecan.com for a period of 90 days

About Tecan
Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2021, Tecan generated sales of CHF 947 million (USD 1,041 million; EUR 877 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Shareholders approve all resolutions on the agendas of Tenaris’s Annual General Meeting and Extraordinary General Meeting of Shareholders1.5.2024 23:10:26 CEST | Press release

LUXEMBOURG, May 01, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced that its annual general meeting of shareholders and its extraordinary general meeting of shareholders, both held on April 30, 2024, approved all resolutions on their agendas. Among other resolutions adopted at the annual general meeting, shareholders acknowledged the Company’s 2023 annual report, containing the consolidated management report and the related management certifications and external auditors’ reports, and the Company’s 2023 annual sustainability report, containing the non-financial statement required by Luxembourg law. The shareholders also approved the consolidated financial statements as of and for the year ended December 31, 2023, and the annual accounts as at December 31, 2023. The annual general meeting also approved an annual dividend of US$0.60 per share (or US$1.20 per ADR), which represents an aggregate sum of approximately US$0.7 billion, and which include

CNH is changing its NYSE ticker symbol to “CNH” on May 201.5.2024 22:30:00 CEST | Press release

Basildon, May 1, 2024 CNH Industrial (NYSE: CNHI) announces that the Company’s common shares listed on the New York Stock Exchange (NYSE) will begin trading under the symbol “CNH” effective Monday, May 20, 2024. This will replace the Company’s current ticker symbol, “CNHI”, marking a return to both our original ticker symbol “CNH” – used until 2013 – and our identity as a leading pureplay provider of equipment, technology and services for agriculture and construction. CNH Industrial N.V. will remain the name of the legal entity. The ticker symbol for the Company’s 3.850% Notes due 2027 will also change from “CNHI 27” to “CNH 27” at the same time. No action is required by the Company's shareholders or bondholders with respect to the ticker symbol changes, as the Company’s common stock and notes will continue to be listed on the NYSE and their CUSIP numbers will remain unchanged. CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breakin

Koelis Announces New Product Release at AUA 2024 to Offer Innovative AI-Enhanced MRI Fusion Biopsy Workflow1.5.2024 20:48:50 CEST | Press release

GRENOBLE, France and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in prostate care, announced today the release of new features at the prestigious American Urological Association Annual Meeting in San Antonio, TX. Koelis will be holding live and interactive demos at its booth #951 from May 2nd to May 5th to demonstrate its novel capacity integrating AI-enhanced prostate MRI features into its exclusive Trinity platform. The Koelis Trinity® system enables urologists to perform 3D targeted “fusion biopsy” in prostate cancer. Trinity integrates 3D ultrasound imaging with proprietary MRI-US fusion image guidance that features the Company’s unique prostate motion tracking software (OBT Fusion®). The compact Koelis Trinity® system does not require interfaces with either external ultrasound equipment or external sensors. The versatility of the Trinity platform is enabling Koelis to lead the ongoing paradigm sh

Awilco Drilling Plc: Keppel denied leave to appeal the ruling of the AR2 arbitration tribunal1.5.2024 20:34:14 CEST | Press release

Further to the stock exchange releases of 23 November 2023 and 15 January 2024 from Awilco Drilling PLC ("Awilco Drilling") regarding the termination of the newbuilding contract between Awilco Rig 2 Pte. Ltd. ("AR2") and Keppel FELS Limited ("KFELS") for the construction of a semi-submersible drilling rig, hull number B382. The Company has today received the decision of the High Court refusing Keppel’s application for leave to appeal the award of the AR2 arbitration tribunal. The award is in AR2's favour in an amount of USD 43.0 million plus interest and legal costs. Unless the parties can mutually agree, the tribunal will issue a further award related to interest and costs. We will revert once the award has been received and the amounts of interest and costs have been determined. Aberdeen, 1 May 2024 For further information please contact: Eric Jacobs, CEO of Awilco Drilling PLC Phone: +47 9529 2271 Cathrine Haavind, Investor Relations of Awilco Drilling PLC Phone: +47 9342 8464 Email

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond1.5.2024 18:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder meeting will take place on May 6, 2024, in order to vote on the proposals published on April 23, 2024. Allschwil, Switzerland – May 1, 2024 Idorsia Ltd (SIX: IDIA) today announced that in relation to the bondholder meeting for holders of its outstanding convertible bonds maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds), Idorsia has improved the consent fee to 8’000’000 Idorsia shares up from 5’000’000. Other elements of the proposal published on April 23, 2024 such as the (i) amendment to the conversion price to CHF 6.00 (from currently CHF 33.95), (ii) extension of the maturity date by six months to January 17, 2025 and (iii) giving Idorsia the option to call the Bonds at par, in full or in part, at any time upon giving ten trading days' notice, remain unchanged. Bondholders can acc

HiddenA line styled icon from Orion Icon Library.Eye